Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation
- PMID: 22218709
- DOI: 10.1007/s10014-011-0077-6
Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation
Abstract
Glioblastomas are highly vascular tumors. Recent preclinical and clinical investigations have revealed that agents targeting angiogenesis may have efficacy against this type of tumor. Antibodies to vascular endothelial growth factor are being studied in this patient population. Unfortunately, treatment inevitably fails. This review provides an update on recent research on the mechanisms by which tumor cells acquire resistance, and discusses recent preclinical and experimental development of novel new-generation anti-angiogenic agents that overcome this problem, especially those based on the molecular mechanisms of tumor vessel formation. The tumor vasculature not only nourishes glioblastomas, but also provides a specialized microenvironment for tumor stem-like cells and for the brain tumor. The factors, pathways, and interactions described in this review provide information about the cell biology of glioblastomas which may ultimately result in new modes of treatment.
Similar articles
-
VEGF inhibitors in brain tumors.Clin Adv Hematol Oncol. 2009 Nov;7(11):753-60, 768. Clin Adv Hematol Oncol. 2009. PMID: 20075834 Review.
-
DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.Cancer Res. 2011 Sep 15;71(18):6073-83. doi: 10.1158/0008-5472.CAN-11-1704. Epub 2011 Jul 29. Cancer Res. 2011. PMID: 21803743
-
Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma.Mol Neurobiol. 2020 May;57(5):2461-2478. doi: 10.1007/s12035-020-01892-8. Epub 2020 Mar 9. Mol Neurobiol. 2020. PMID: 32152825 Free PMC article. Review.
-
[Angiogenesis and anti-angiogenic strategies for glioblastoma].Bull Cancer. 2005 Apr;92(4):360-72. Bull Cancer. 2005. PMID: 15888393 Review. French.
-
Insulin-like growth factor binding protein-4 (IGFBP-4) is a novel anti-angiogenic and anti-tumorigenic mediator secreted by dibutyryl cyclic AMP (dB-cAMP)-differentiated glioblastoma cells.Glia. 2006 Jun;53(8):845-57. doi: 10.1002/glia.20345. Glia. 2006. PMID: 16586492
Cited by
-
Longitudinal in-vivo OCM imaging of glioblastoma development in the mouse brain.Biomed Opt Express. 2020 Aug 12;11(9):5003-5016. doi: 10.1364/BOE.400723. eCollection 2020 Sep 1. Biomed Opt Express. 2020. PMID: 33014596 Free PMC article.
-
A systematic review and meta-analysis on the differentiation of glioma grade and mutational status by use of perfusion-based magnetic resonance imaging.Insights Imaging. 2022 Jun 7;13(1):102. doi: 10.1186/s13244-022-01230-7. Insights Imaging. 2022. PMID: 35670981 Free PMC article. Review.
-
An Efficient and Flexible Method for Deconvoluting Bulk RNA-Seq Data with Single-Cell RNA-Seq Data.Cells. 2019 Sep 27;8(10):1161. doi: 10.3390/cells8101161. Cells. 2019. PMID: 31569701 Free PMC article.
-
Macrovascular Networks on Contrast-Enhanced Magnetic Resonance Imaging Improves Survival Prediction in Newly Diagnosed Glioblastoma.Cancers (Basel). 2019 Jan 14;11(1):84. doi: 10.3390/cancers11010084. Cancers (Basel). 2019. PMID: 30646519 Free PMC article.
-
Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.Oncotarget. 2015 Dec 29;6(42):44563-78. doi: 10.18632/oncotarget.6310. Oncotarget. 2015. PMID: 26575424 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
